Algernon Health Announces Name Change to “Grey Matters Health” and 10:1 Share Consolidation
CSE: GREY | OTCQB: AGNPF | Frankfurt: AGW0
Overview
Grey Matters Health (formerly Algernon Health Inc.) is entering a defining new chapter, one that signals far more than a corporate rebrand. Effective April 21, the company began trading on the CSE under its new name and ticker symbol, GREY, alongside a 10:1 share consolidation that reduced outstanding shares to approximately 5.4 million, creating a tighter capital structure and a market cap of approximately C$2.7 million at a recent price of C$0.50.
This is not cosmetic housekeeping; it is a strategic reset designed to align the public market identity with where management believes the real value lies: neuroimaging and early Alzheimer’s detection.
Key Highlights
- Corporate name changed from Algernon Health Inc. to Grey Matters Health Inc., effective April 21, 2026
- New CSE ticker symbol: GREY (OTCQB: AGNPF, Frankfurt: AGW0)
- 10:1 share consolidation reduced outstanding shares to approximately 5,418,243
- Market cap of approximately C$2.7 million at a recent price of C$0.50
- Repositioning around NovaScan Neuroimaging Clinics™, a planned U.S. network of specialized brain PET scanning clinics
- First clinic planned at the HCA Florida University Medical Office Building in Davie, with a projected opening in summer 2026
- Addressable market for neuroimaging services estimated at US$6.9 billion
- C$1 million private placement launched at C$0.40 per unit to fund the first U.S. clinic and working capital
NovaScan Neuroimaging Strategy
GREY is repositioning itself around its NovaScan Neuroimaging Clinics™, a planned U.S. network of specialized brain PET scanning clinics focused on the early-stage detection of beta-amyloid plaques associated with Alzheimer’s Disease, while also serving broader neurodegenerative and neurological conditions including Parkinson’s, dementia, epilepsy, multiple sclerosis, neuro-oncology, and other brain disorders. This represents an emerging market estimated at US$6.9 billion. The first clinic is planned at the HCA Florida University Medical Office Building in Davie, with a projected opening in summer 2026.
To support this rollout, the company launched a C$1 million private placement at C$0.40 per unit, with each unit consisting of one common share and one warrant exercisable at C$0.60 for 24 months, to fund its first U.S. brain-specific neuroimaging clinic and working capital needs.
ArcStone’s View
The market likes clarity: new name, new symbol, lower float, and a sharper thesis.
Grey Matters is no longer selling a biotech experiment; it is building healthcare infrastructure. With 7 million Americans affected by Alzheimer’s and PET scans increasingly required for treatment access, the opportunity gap is real.
New start. New story. Now it comes down to execution.
If Grey Matters can successfully establish even the first few high-performing diagnostic centers, the market may begin valuing it less as a speculative microcap and more as a specialized healthcare operator conquering Alzheimer’s, one diagnostic center at a time.
About Grey Matters Health Inc.
Grey Matters Health (formerly Algernon Health) is a Canadian healthcare company focused on the provision of brain-specific PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease, and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders including Parkinson’s disease. The company also has a program for Repirinast, a repurposed drug for CKD, and is the parent company of Algernon NeuroScience, a wholly owned subsidiary advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery.
Disclaimer and Forward-Looking Statements
The information contained herein is provided by ArcStone Financial Pulse Inc. (“ArcStone Financial Pulse”), a subsidiary of ArcStone Securities and Investments Corp. (“ArcStone”), for informational purposes only. It is not, and under no circumstances should it be construed as, an offer to sell or a solicitation of an offer to buy any securities or other financial instruments in any jurisdiction. This content is not a research report within the meaning of FINRA Rules 2241 or 2242 and does not constitute a research report under any applicable securities laws.
Certain statements contained herein may constitute “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements are based on current expectations, estimates, and assumptions that involve known and unknown risks and uncertainties which may cause actual results or developments to differ materially from those expressed or implied. These statements often include words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “target,” or similar expressions. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Except as required by law, ArcStone undertakes no obligation to update or revise any forward-looking information.
This content is not intended as investment advice or a recommendation to buy or sell any security and does not take into account the investment objectives, financial situation, or needs of any individual. Investors should consult their own professional advisors before making any investment decisions.
ArcStone Securities and Investments Corp. is not a registered broker-dealer and does not provide investment advice or recommendations. All registrable activities in the United States are conducted through ArcStone Securities LLC (CRD# 306029) and Kingswood Capital Partners LLC (CRD# 288898), both FINRA-registered broker-dealers, members SIPC. ArcStone Canada Inc. is not registered as a dealer in any Canadian jurisdiction; registrable dealing activities in Canada are conducted through appropriately registered affiliates. ArcStone Financial Pulse Inc. is owned by the same parent entity as ArcStone Securities LLC and ArcStone Kingswood, the investment banking division of Kingswood Capital Partners LLC. This common ownership represents a structural conflict of interest. The issuer featured in this article (the “Company”) may be a current or former client of ArcStone or any of its subsidiaries and affiliates. Where ArcStone or its subsidiaries and affiliates have received or have been promised consideration for services provided to the Company, such consideration may include cash, stock, stock options, warrants, and/or Restricted Stock Units (RSUs) for the provision of corporate advisory, investor relations, digital media, or capital markets consulting services. This relationship represents a potential conflict of interest, as ArcStone may be perceived to have an incentive to present the Company in a favorable light. The principals, directors, officers, employees, and related entities of ArcStone and its affiliates may, from time to time, own, buy, or sell securities or derivatives of the Company or its affiliates.
